Cure My Disease

Don't miss your cure!

 Log in / Sign up

Kratom patch could ease stubborn neck pain without pills

NCT ID NCT07713771

Symptom relief Sponsor: Prince of Songkla University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 20, 2026 · Last updated Aug 11, 2026 · Updated 3 times

Summary

This study tests whether a skin patch containing mitragynine, the main active compound from the kratom plant, can reduce pain in people with chronic myofascial pain syndrome in the upper neck and shoulder muscles. Participants aged 18 to 50 with pain lasting over three months will receive either the active patch or a placebo patch. The goal is to see if the patch provides better pain relief than a dummy patch, offering a potential alternative to oral medications.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
a topical patch containing 10 mg of mitragynine, the main active compound from the kratom plant
What this could lead to
If effective, this patch could offer a new, non-oral option for managing chronic muscle pain without the side effects of oral painkillers.
What could go wrong
This is a small, early-phase trial, so results may not apply to everyone. The patch may not work better than a placebo, and skin irritation is possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

About 64 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Oct 2026

An estimate. Start dates often move.

Expected to finish

Oct 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 50 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * \- Patients aged 18-50 years. * Experiencing neck or shoulder pain for more than 3 months. * Diagnosed with myofascial pain syndrome, with the most tender trigger point located in the upper trapezius muscle and a pain score between 30-60 mm measured using the Visual Analogue Scale (VAS). Exclusion Criteria: * \- History of other neck-related conditions (e.g., whiplash injury, cervical radiculopathy, fibromyalgia syndrome, cervical spine surgery and/or fracture). * History of systemic diseases (e.g., rheumatism, multiple sclerosis, cervical myelopathy), hepatitis, liver failure, or kidney disease (serum creatinine \> 2.0 mg/dL). * Symptoms or conditions contraindicating the use of patches, such as wounds or infections at the painful site. * History of allergy to paracetamol or kratom. * History of allergy to adhesive patches/plasters. * Pregnant or breastfeeding women. * Receipt of treatment with analgesics other than paracetamol, physical therapy, dry needling/acupuncture, massage, or topical medications within the previous week. * Individuals who are unable to read or write.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Myofascial pain syndrome - neck are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

myofascial pain syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Myofascial pain syndrome - neck Topical analgesia

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Prince of Songkla university

    Songkhla, Changwat Songkhla, 90110, Thailand

More trials for these conditions

Other studies related to the condition(s) this trial covers.